person · Reporting owner

HERSHBERG ROBERT

Disclosed activity across 8 companies

Tapewire entity: 21219
SEC CIK: 0001274139

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARS Pharmaceuticals, Inc.SBTX · Entity 883	Director	June 10, 2022	June 13, 2022
Adaptive Biotechnologies CorpADPT · Entity 1126	Director	August 18, 2026	August 20, 2026
Atai Beckley N.V.ATAI · Entity 72536	Director	November 05, 2025	November 07, 2025
FATE THERAPEUTICS INCFATE · Entity 5968	Director	June 06, 2023	June 07, 2023
RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008	Director	October 06, 2026	October 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARS Pharmaceuticals, Inc.

Report date June 10, 2022 · Filed June 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09	Direct	18,000	Reported balance After 2022-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Adaptive Biotechnologies Corp

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	46,683	Ending reported balance After 2026-08-18 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-08-18 · Exercise / conversion · Acquired 15,000 · Balance 77,347 Row 2 · 2026-08-18 · Sale · Disposed 15,000 · Balance 62,347 F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-08-18 · Sale · Disposed 15,664 · Balance 46,683 F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2026-10-18	Direct	0	Reported balance After 2026-08-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-18 · Exercise / conversion · Disposed 15,000 · Balance 0 F3: The option was fully vested and exercisable and would have expired on October 18, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The option was fully vested and exercisable and would have expired on October 18, 2026.

Atai Beckley N.V.

Report date November 05, 2025 · Filed November 07, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2030-07-05	Direct	456,011	Reported balance After 2025-11-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-11-05 · Grant · Acquired 456,011 · Balance 456,011 F1: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement. F2: The stock option is fully vested as of the grant date.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2030-06-07	Direct	97,716	Reported balance After 2025-11-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-11-05 · Grant · Acquired 97,716 · Balance 97,716 F1: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement. F2: The stock option is fully vested as of the grant date.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2032-10-20	Direct	62,394	Reported balance After 2025-11-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-11-05 · Grant · Acquired 62,394 · Balance 62,394 F1: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement. F2: The stock option is fully vested as of the grant date.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.48 · Expires 2035-11-05	Direct	103,000	Reported balance After 2025-11-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-11-05 · Grant · Acquired 103,000 · Balance 103,000 F3: The stock option shall vest in full on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: On November 5, 2025, the Issuer completed its previously announced acquisition of the entire issued share capital of Beckley Psytech Limited ("Beckley Psytech") not already owned by the Issuer (the "Acquisition") from the shareholders of Beckley Psytech, pursuant to that certain Share Purchase Agreement, dated as of June 2, 2025, by and among the parties thereto, as amended (the "Purchase Agreement"). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement.

F2: The stock option is fully vested as of the grant date.

F3: The stock option shall vest in full on the first anniversary of the grant date.

FATE THERAPEUTICS INC

Report date June 06, 2023 · Filed June 07, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.52 · Expires 2033-06-06	Direct	40,000	Reported balance After 2023-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-06 · Grant · Acquired 40,000 · Balance 40,000 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

RECURSION PHARMACEUTICALS, INC.

Report date October 06, 2026 · Filed October 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	162,156	Ending reported balance After 2026-10-06 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-10-06 · Exercise / conversion · Acquired 25,000 · Balance 187,156 F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025. Row 2 · 2026-10-06 · Sale · Disposed 25,000 · Balance 162,156
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2030-03-19	Direct	500,000	Reported balance After 2026-10-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-10-06 · Exercise / conversion · Disposed 25,000 · Balance 500,000 F2: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Date exercisable varies by tranche.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025.

F2: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Date exercisable varies by tranche.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AtaiBeckley Inc.

Report date September 11, 2026 · Filed September 11, 2026

Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2030-06-07	Direct	Reported balance After 2026-09-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-11 · Disposition to issuer · Disposed 48,858 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2030-07-08	Direct	Reported balance After 2026-09-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-11 · Disposition to issuer · Disposed 404,869 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2032-10-20	Direct	Reported balance After 2026-09-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-11 · Disposition to issuer · Disposed 62,394 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.48 · Expires 2035-11-05	Direct	Reported balance After 2026-09-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04	Direct	Reported balance After 2026-09-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0 F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.

F2: At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).

HilleVax, Inc.

Report date September 17, 2025 · Filed September 17, 2025

Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-09-17 transaction · row 1 1 source row Row 1 · 2025-09-17 · Other · Disposed 1,101,498 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

NanoString Technologies Inc

Report date April 18, 2022 · Filed April 18, 2022

Section 16 reporting ended · disclosed 2022-04-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,716	Reported balance After 2022-04-18 transaction · row 1 1 source row Row 1 · 2022-04-18 · Exercise / conversion · Acquired 3,306 · Balance 10,716 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
Common StockSEC Table II · derivative / convertible security	Direct	584	Reported balance After 2022-04-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-04-18 · Exercise / conversion · Disposed 3,306 · Balance 584 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F2: In recognition of his service to the Board of Directors of the Issuer, Dr. Hershberg's non-vested RSU awards were partially accelerated effective April 18, 2022 immediately prior to the effectiveness of his resignation as a member of the Board of Directors. F3: 100% of the RSUs vest on the earlier of the one year anniversary of June 16, 2021 or on the date immediately prior to the 2022 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.

F2: In recognition of his service to the Board of Directors of the Issuer, Dr. Hershberg's non-vested RSU awards were partially accelerated effective April 18, 2022 immediately prior to the effectiveness of his resignation as a member of the Board of Directors.

F3: 100% of the RSUs vest on the earlier of the one year anniversary of June 16, 2021 or on the date immediately prior to the 2022 annual meeting of stockholders.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 17, 2020 Filed Aug 19, 2020 16:40 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionStock Option (right to buy) · Derivative	1,500	$11.20 Strike: $11.20	$16,800.00	Disclosure SEC source: 0001401708-20-000162 · wf-form4_159786959791161.xml · derivative · entry 5 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,188 Underlying: Common Stock · 1,500 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 50% of the shares subject to the Option vest on the one year anniversary of March 2, 2015 (the "Vesting Commencement Date") and thereafter the remaining 50% of the total shares vest in twelve equal monthly installments on each monthly anniversary of the Vesting Commencement Date, subject to continued service as a director through each vesting date. Read SEC document
August 17, 2020 Filed Aug 19, 2020 16:40 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	240	$39.26	$9,422.40	Disclosure SEC source: 0001401708-20-000162 · wf-form4_159786959791161.xml · nonDerivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.15 to $39.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
August 17, 2020 Filed Aug 19, 2020 16:40 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	846	$38.44	$32,520.24	Disclosure SEC source: 0001401708-20-000162 · wf-form4_159786959791161.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,130 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.13 to $39.11, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
August 17, 2020 Filed Aug 19, 2020 16:40 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	414	$37.71	$15,611.94	Disclosure SEC source: 0001401708-20-000162 · wf-form4_159786959791161.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,976 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $37.08 to $37.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
August 17, 2020 Filed Aug 19, 2020 16:40 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	1,500	$11.20	$16,800.00	Disclosure SEC source: 0001401708-20-000162 · wf-form4_159786959791161.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 15, 2020 Filed Jul 18, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionStock Option (Right to Buy) · Derivative	2,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001209191-20-043011 · doc4.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
July 15, 2020 Filed Jul 18, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	500	$44.58	$22,290.00	Disclosure SEC source: 0001209191-20-043011 · doc4.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.03 to 43.85, inclusive. Read SEC document
July 15, 2020 Filed Jul 18, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	1,500	$43.60	$65,400.00	Disclosure SEC source: 0001209191-20-043011 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.06 to $44.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document
July 15, 2020 Filed Jul 18, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionCommon Stock	2,000	$0.45	$900.00	Disclosure SEC source: 0001209191-20-043011 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document
July 15, 2020 Filed Jul 17, 2020 16:53 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionStock Option (right to buy) · Derivative	1,500	$11.20 Strike: $11.20	$16,800.00	Disclosure SEC source: 0001401708-20-000146 · wf-form4_159501921328101.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,688 Underlying: Common Stock · 1,500 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 50% of the shares subject to the Option vest on the one year anniversary of March 2, 2015 (the "Vesting Commencement Date") and thereafter the remaining 50% of the total shares vest in twelve equal monthly installments on each monthly anniversary of the Vesting Commencement Date, subject to continued service as a director through each vesting date. Read SEC document
July 15, 2020 Filed Jul 17, 2020 16:53 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	1,155	$36.40	$42,042.00	Disclosure SEC source: 0001401708-20-000146 · wf-form4_159501921328101.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $35.98 to $36.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
July 15, 2020 Filed Jul 17, 2020 16:53 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	345	$35.31	$12,181.95	Disclosure SEC source: 0001401708-20-000146 · wf-form4_159501921328101.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,045 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $234.88 to $35.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
July 15, 2020 Filed Jul 17, 2020 16:53 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	1,500	$11.20	$16,800.00	Disclosure SEC source: 0001401708-20-000146 · wf-form4_159501921328101.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 16, 2020 Filed Jun 17, 2020 19:45 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantRestricted Stock Units · Derivative	5,520	$0.00	$0.00	Disclosure SEC source: 0001401708-20-000135 · wf-form4_159243748503301.xml · derivative · entry 6 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,520 Underlying: Common Stock · 5,520 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F7 · derivative.exercise_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 16, 2020 or on the date immediately prior to the 2021 annual meeting of stockholders. F7 · derivative.expiration_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 16, 2020 or on the date immediately prior to the 2021 annual meeting of stockholders. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionStock Option (Right to Buy) · Derivative	2,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001209191-20-037451 · doc4.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	984	$43.42	$42,725.28	Disclosure SEC source: 0001209191-20-037451 · doc4.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.03 to 43.85, inclusive. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	1,016	$42.59	$43,271.44	Disclosure SEC source: 0001209191-20-037451 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 984 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.00 to $42.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionCommon Stock	2,000	$0.45	$900.00	Disclosure SEC source: 0001209191-20-037451 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document
June 15, 2020 Filed Jun 17, 2020 19:45 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionStock Option (right to buy) · Derivative	1,500	$7.47 Strike: $11.20	$11,205.00	Disclosure SEC source: 0001401708-20-000135 · wf-form4_159243748503301.xml · derivative · entry 5 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,188 Underlying: Common Stock · 1,500 shares Expires 2025-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 50% of the shares subject to the Option vest on the one year anniversary of March 2, 2015 (the "Vesting Commencement Date") and thereafter the remaining 50% of the total shares vest in twelve equal monthly installments on each monthly anniversary of the Vesting Commencement Date, subject to continued service as a director through each vesting date. Read SEC document
June 15, 2020 Filed Jun 17, 2020 19:45 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionRestricted Stock Units · Derivative	1,890	$0.00	$0.00	Disclosure SEC source: 0001401708-20-000135 · wf-form4_159243748503301.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,890 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. F5 · derivative.exercise_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 18, 2019 or on the date immediately prior to the 2020 annual meeting of stockholders. F5 · derivative.expiration_date: 100% of the RSUs vest on the earlier of the one year anniversary of June 18, 2019 or on the date immediately prior to the 2020 annual meeting of stockholders. Read SEC document
June 15, 2020 Filed Jun 17, 2020 19:45 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	1,500	$30.79	$46,185.90	Disclosure SEC source: 0001401708-20-000135 · wf-form4_159243748503301.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890 F2 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.11, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
June 15, 2020 Filed Jun 17, 2020 19:45 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	1,500	$11.20	$16,800.00	Disclosure SEC source: 0001401708-20-000135 · wf-form4_159243748503301.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2020 Filed Jun 17, 2020 19:45 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	1,890	Not disclosed	Not disclosed	Disclosure SEC source: 0001401708-20-000135 · wf-form4_159243748503301.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis. Read SEC document
May 15, 2020 Filed May 19, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionStock Option (Right to Buy) · Derivative	2,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001209191-20-030301 · doc4.xml · derivative · entry 5 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
May 15, 2020 Filed May 19, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	398	$36.10	$14,367.80	Disclosure SEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.89 to 36.33, inclusive. Read SEC document
May 15, 2020 Filed May 19, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	400	$35.23	$14,092.00	Disclosure SEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.82 to 35.68, inclusive. Read SEC document
May 15, 2020 Filed May 19, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	1,202	$34.14	$41,036.28	Disclosure SEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.75 to $34.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document
May 15, 2020 Filed May 19, 2020 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionCommon Stock	2,000	$0.45	$900.00	Disclosure SEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document
May 15, 2020 Filed May 18, 2020 18:13 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock · Derivative	10,168	$7.47 Strike: $7.47	$75,954.96	Disclosure SEC source: 0001401708-20-000115 · wf-form4_158983996309038.xml · derivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,168 shares Expires 2027-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the Option vest on the one year anniversary of January 1, 2018. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document
May 15, 2020 Filed May 18, 2020 18:13 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	3,715	$31.20	$115,908.00	Disclosure SEC source: 0001401708-20-000115 · wf-form4_158983996309038.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $31.07 to $31.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
May 15, 2020 Filed May 18, 2020 18:13 UTC	NanoString Technologies Inc NSTG · Entity 15988	SaleCommon Stock	6,453	$30.61	$197,526.33	Disclosure SEC source: 0001401708-20-000115 · wf-form4_158983996309038.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,715 F1 · kind: The sales reported by Dr. Hershberg were effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2020. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
May 15, 2020 Filed May 18, 2020 18:13 UTC	NanoString Technologies Inc NSTG · Entity 15988	Exercise / conversionCommon Stock	10,168	$7.47	$75,954.96	Disclosure SEC source: 0001401708-20-000115 · wf-form4_158983996309038.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2020 Filed May 5, 2020 20:14 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (right to buy) · Derivative	16,000	Not disclosed Strike: $26.59	Not disclosed	Disclosure SEC source: 0001209191-20-027086 · doc4.xml · derivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-01 F2 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document
May 01, 2020 Filed May 5, 2020 20:14 UTC	FATE THERAPEUTICS INC FATE · Entity 5968	GrantStock Option (right to buy) · Derivative	24,000	Not disclosed Strike: $26.59	Not disclosed	Disclosure SEC source: 0001209191-20-027086 · doc4.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning on June 1, 2020 such that this option is fully exercisable on May 1, 2023. Read SEC document
April 23, 2020 Filed Apr 28, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001209191-20-025881 · doc4.xml · derivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
April 23, 2020 Filed Apr 28, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	25,000	$29.77	$744,250.00	Disclosure SEC source: 0001209191-20-025881 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.41 to 30.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document
April 23, 2020 Filed Apr 28, 2020 00:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionCommon Stock	25,000	$0.45	$11,250.00	Disclosure SEC source: 0001209191-20-025881 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document
February 13, 2020 Filed Feb 18, 2020 12:05 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantStock Option (Right to Buy) · Derivative	8,888	$0.00 Strike: $31.71	$0.00	Disclosure SEC source: 0001209191-20-009867 · doc4.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:13 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantRestricted Stock Units · Derivative	1,890	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001401708-19-000154 · wf-form4_156106162154487.xml · derivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,890 Underlying: Common Stock · 1,890 shares Expires not disclosed F2 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3 · derivative.exercise_date: 100% of the RSUs vest on the earlier of the one-year anniversary of June 18, 2019 or the date immediately prior to the 2020 annual meeting of stockholders. F3 · derivative.expiration_date: 100% of the RSUs vest on the earlier of the one-year anniversary of June 18, 2019 or the date immediately prior to the 2020 annual meeting of stockholders. Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:13 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantStock Options (right to buy) · Derivative	3,857	$0.00 Strike: $26.45	$0.00	Disclosure SEC source: 0001401708-19-000154 · wf-form4_156106162154487.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,857 Underlying: Common Stock · 3,857 shares Expires 2029-06-18 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the earlier of the one-year anniversary of June 18, 2019 or the date immediately prior to the 2020 annual meeting of stockholders. Read SEC document
March 25, 2019 Filed Mar 27, 2019 16:30 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantCommon Stock · Derivative	4,410	$0.00 Strike: $23.34	$0.00	Disclosure SEC source: 0001401708-19-000109 · wf-form4_155371861280393.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,410 Underlying: Common Stock · 4,410 shares Expires 2029-03-25 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the the date prior to the day of the Company's 2019 annual meeting of stockholders. Read SEC document
January 01, 2018 Filed Jan 3, 2018 18:19 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantCommon Stock · Derivative	10,168	$0.00 Strike: $7.47	$0.00	Disclosure SEC source: 0001401708-18-000013 · wf-form4_151502157001088.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,168 Underlying: Common Stock · 10,168 shares Expires 2027-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the one year anniversary of January 1, 2018. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document
January 01, 2017 Filed Jan 4, 2017 18:04 UTC	NanoString Technologies Inc NSTG · Entity 15988	GrantStock Option (Right to Buy) · Derivative	8,611	$0.00 Strike: $22.30	$0.00	Disclosure SEC source: 0001209191-17-001333 · doc4.xml · derivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,611 Underlying: Common Stock · 8,611 shares Expires 2026-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the one year anniversary of January 1, 2017. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.